S&P ASX All Technology

US Dollar vs AUD

Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.

Get Started

SGMO Sangamo Therapeutics Inc

0.5364

-0.0088 (-1.61%)

01 Jun 2024 - Closed

Delayed by 15 minutes

Form 3 - Initial statement of beneficial ownership of securities

Sangamo Therapeutics (NASDAQ:SGMO)
Historical Stock Chart
From May 2024 to Jun 2024

Click Here for more Sangamo Therapeutics Charts.

Sangamo Therapeutics (NASDAQ:SGMO)
Historical Stock Chart
From Jun 2023 to Jun 2024

Click Here for more Sangamo Therapeutics Charts.

Sangamo Therapeutics Inc News

Form 4 - Statement of changes in beneficial ownership of securities
Thursday 30 May 2024 (3 days ago) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Thursday 30 May 2024 (3 days ago) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Thursday 30 May 2024 (3 days ago) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Thursday 30 May 2024 (3 days ago) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Thursday 30 May 2024 (3 days ago) • Edgar (US Regulatory)

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Friday 10 May 2024 (3 weeks ago) • Edgar (US Regulatory)

Form 8-K - Current report
Friday 10 May 2024 (3 weeks ago) • Edgar (US Regulatory)

Sangamo Therapeutics Reports Recent Business Highlights and First Quarter 2024 Financial Results
Friday 10 May 2024 (3 weeks ago) • Business Wire

Sangamo Therapeutics Presents Next-Generation Modular Integrase Technology Engineered to Enable Large-Scale Genome Editing
Thursday 9 May 2024 (3 weeks ago) • Business Wire

Sangamo Therapeutics Announces First Quarter 2024 Conference Call and Webcast
Friday 3 May 2024 (4 weeks ago) • Business Wire

Sangamo Therapeutics to Present Neurology-Focused Pre-Clinical Data From Its Epigenetic Regulation, Capsid Delivery and Genome Engineering Platforms at the 27th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)
Tuesday 23 April 2024 (1 month ago) • Business Wire

Sangamo Therapeutics Announces Pricing of $24.0 Million Registered Direct Offering
Friday 22 March 2024 (2 months ago) • Business Wire

More Sangamo Therapeutics Inc News Articles

XS2665727272 20251010 0....

Bnp Paribas 3.65% 09sep2...

Pelican Resources

BNS Token [OLD]

G Medical Innovations (PK)

Barclays Bank Plc Autoca...

Belo Sun Mining

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions